C4 Therapeutics is a private biotechnology company developing a new class of drugs based on Targeted Protein Degradation (TPD) to address a broad range of life-threatening and life-impairing diseases. C4T’s Degronimid™ platform uses small molecule drugs to direct the machinery of the ubiquitin-proteasome system to selectively degrade disease-relevant proteins for therapeutic benefit. Leveraging this distinctive mechanism provides new opportunities to target traditionally difficult to treat diseases and drug resistance. The wide-ranging potential of the Degronimid approach underpins C4T’s internal drug discovery programs as well as strategic partnerships with leading global pharmaceutical and biotechnology firms.
Founder and CEO: Marc Cohen
Founders: Ken Anderson, Marc Cohen, Jay Bradner and Nathanael Gray
CSO: Andy Phillips
CAO: Andrea Armstrong
CBO: Tom Needham
Please click here for C4 job opportunities.
FOLLOW C4 THERAPEUTICS: